Noribogainalog
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine.[1][2] It is a simplified analogue of noribogaine.[1][2]
| |
 | |
| Clinical data | |
|---|---|
| Other names | Nor-IBG; 9-Hydroxyibogaminalog |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H16N2O |
| Molar mass | 216.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The drug acts as a potent serotonin 5-HT2A receptor partial agonist (EC50 ≈ 90 nM; Emax = 35%).[2] It also has activity as a dopamine transporter (DAT) chaperone.[3] Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures.[2] However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin.[2] The drug shows relatively low expected blood–brain barrier permeability.[2]
History
Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.[1]